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H epatocellular carcinoma (HCC) is the ﬁfth-lead-ing cause of cancer-related deaths in Japan [1] 
and the third-leading cause of cancer-related deaths 
worldwide [2].  Hepatectomy is one of the standard 
treatments for HCC.  Advances in surgical techniques 
and perioperative management have improved the 
in-hospital mortality rate after surgery and the overall 
survival rate for HCC; however,  further advances in 
surgical techniques are required to prevent the recur-
rence of intrahepatic or extrahepatic HCC that often 
occurs after a hepatectomy [3,4].  A preoperative 
assessment of prognostic factors is thus required to 
determine the appropriate treatment,  including sur-
gery.  To identify the prognostic factors in patients 
with HCC,  previous studies have focused on host-spe-
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Sarcopenia following liver surgery has been reported as a predictor of poor prognosis.  Here we inves-
tigated predictors of outcomes in patients with hepatocellular carcinoma (HCC) and attempted to estab-
lish a new comprehensive preoperative assessment protocol.  We retrospectively analyzed the cases of 
254 patients who underwent curative hepatectomy for HCC with Child-Pugh classiﬁcation A at our 
hospital between January 2007 and December 2013.  Sarcopenia was evaluated by computed tomogra-
phy measurement.  The inﬂuence of sarcopenia on outcomes was evaluated.  We used multivariate 
analyses to assess the impact of prognostic factors associated with outcomes,  including sarcopenia.  Of 
the 254 patients,  118 (46.5 ) met the criteria for sarcopenia,  and 32 had an American Society of 
Anesthesiologists (ASA) physical status 3.  The sarcopenic group had a signiﬁcantly lower 5-year 
overall survival rate than the non-sarcopenic group (58.2  vs. 82.4 ,  p＝0.0002).  In multivariate anal-
yses of prognostic factors,  sarcopenia was an independent predictor of poor survival (hazard ratio 
[HR]＝2.28,  p＝0.002) and poor ASA status (HR＝3.17,  p＝0.001).  Sarcopenia and poor ASA status 
are independent preoperative predictors for poor outcomes after hepatectomy.  The preoperative iden-
tiﬁcation of sarcopenia and ASA status might enable the development of comprehensive approaches to 
assess surgical eligibility.
Key words: sarcopenia,  American Society of Anesthesiologists physical status,  hepatectomy,  hepatocellular 
carcinoma,  prognostic factor
Received June 2, 2016 ; accepted August 8, 2016.
＊Corresponding author. Phone : ＋81-86-223-7151; Fax : ＋81-86-221-8775
E-mail : twin1957yagi2000@yahoo.co.jp (T. Yagi)
Conﬂict of Interest Disclosures: No potential conﬂict of interest relevant 
to this article was reported.
ciﬁc and tumor-speciﬁc factors related to clinical out-
comes [5].  However,  a comprehensive assessment of 
the preoperative prognostic factors has not yet been 
established.
　 The American Society of Anesthesiologists (ASA) 
physical status classiﬁcation system has been used to 
evaluate the general preoperative condition of patients 
and was reported to be a predictor of poor outcome 
following hepatectomy [6,7].  A recent study sug-
gested that sarcopenia,  which is characterized by 
skeletal muscle depletion and is an objective predictor 
of frailty,  is independently associated with poor out-
comes in many types of cancers [8].  Regarding HCC,  
sarcopenia was recently identiﬁed as a poor prognos-
tic factor of long-term outcome after hepatectomy,  
independent of tumor-speciﬁc factors [7,9],  and is 
reportedly linked to chemotherapy toxicity [10].  
Sarcopenia was also identiﬁed as a poor prognostic 
factor for liver transplantation [11-14].  However,  
the deﬁnition of sarcopenia remains controversial,  and 
a precise preoperative evaluation method that detects 
sarcopenia,  in combination with other predictors,  is 
urgently required for safer hepatic surgery.
　 We therefore designed the present study to inves-
tigate the impact of sarcopenia on overall survival as 
well as other predictors of overall survival,  and to 
subsequently establish a new comprehensive preoper-
ative scoring system.  We hypothesized that sarcopenia 
is signiﬁcantly associated with poor prognosis in 
patients undergoing hepatectomy for HCC.
Materials and Methods
　 Patients. This study was approved by the Ethics 
Committee of the Okayama University Graduate 
School of Medicine,  Dentistry and Pharmaceutical 
Sciences and Okayama University Hospital (approval 
no. 1743) and conducted in accordance with the 
Declaration of Helsinki.  Due to the retrospective 
nature of the study,  the need for informed consent 
was waived.  We retrospectively reviewed the medical 
records of consecutive patients who underwent cura-
tive resection of HCC at the Okayama University 
Hospital (Okayama,  Japan) in the 7-year period from 
January 2007 to December 2013.  To eliminate the 
inﬂuence of the severity of liver function,  the patients 
enrolled were limited to those with Child-Pugh classi-
ﬁcation A.
　 Clinical data. From our database,  the follow-
ing demographic and clinical data were evaluated as 
preoperative factors: sex,  age,  height,  weight,  body 
mass index (BMI),  ASA physical status,  etiology of 
liver disease,  laboratory values (albumin level and 
platelet count),  tumor marker levels,  liver function 
evaluated using the Child-Pugh classiﬁcation,  and 
comorbidities.  The ASA physical status was preoper-
atively evaluated by anesthesiologists.
　 Surgical procedure and pathological exam-
ination. Details of the surgical techniques have 
been reported [15].  Data for the surgical procedure,  
type of hepatectomy,  operative time,  and amount of 
blood loss were recorded as operative factors.  A 
tumor specimen was evaluated for pathological factors 
by a pathologist according to the rules of the Liver 
Cancer Study Group of Japan [16].
　 Short-term and long-term outcomes. Posto-
perative complications after surgery were assessed 
using the Clavien-Dindo classiﬁcation [17],  according 
to the major complications that are deﬁned as Clavien 
grade 3.  All patients underwent a follow-up exam-
ination every 3 or 6 months at our institution or 
another aﬃliated hospital to examine their physical 
condition,  liver function,  and recurrence.  The last 
data of this cohort were updated in February 2016.
　 Image analysis and definition of sarcopenia.
Diagnostic computed tomography (CT) images taken 
within 3 months prior to surgery were chosen and 
evaluated using a CT image analysis system (Synapse 
Vincent,  Fujiﬁlm Medical,  Tokyo).  The total cross- 
sectional skeletal muscle area at the level of the third 
lumbar vertebra (L3) was measured by assessing pre-
operative CT images using Hounsﬁeld unit thresholds 
of －29 to ＋150 for skeletal muscle (Fig.  1) [18].  
The L3 region includes the psoas,  erector spinae,  
quadratus lumborum,  transversus abdominis,  external 
and internal oblique abdominal muscles,  and the rectus 
abdominis muscle.
　 In this study,  the skeletal muscle area (cm2) was 
divided by height (m2) to obtain the skeletal muscle 
index (SMI,  cm2/m2).  The sex-speciﬁc cut-oﬀ values 
for the SMI associated with overall mortality obtained 
by optimum stratiﬁcation [19,20] were 46.4 cm2/m2 
for men (area under the curve [AUC]＝0.656) and 
37.6 cm2/m2 for women (AUC＝0.561).  Patients with 
values below these cut-oﬀs were considered to have 
sarcopenia.
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　 Statistical analysis. JMP version 10 software 
(SAS Institute,  Cary,  NC) was used for statistical 
analysis.  Data are presented as mean,  median,  and 
standard deviation for continuous variables.  Categorical 
data are presented as proportions.  Diﬀerences between 
groups were assessed using the Mann-Whitney U-test 
for continuous variables and Fisherʼs exact test or 
χ2-test for categorical variables.  Overall survival 
curves were calculated using the Kaplan-Meier method 
and analyzed using the log rank test.  To investigate 
the impact of prognostic factors associated with over-
all survival,  we used the Cox proportional hazard 
model for univariate and multivariate analyses,  and 
hazard ratios (HRs) and 95  conﬁdence intervals were 
calculated.  A p-value ＜0.05 was considered signiﬁcant.
Results
　 Of the 273 patients who underwent curative resec-
tion and who were considered eligible for this analy-
sis,  12 were excluded because of unavailable preoper-
ative CT images,  and 7 were excluded for a Child-
Pugh classification B. The clinicopathological 
characteristics of the remaining 254 patients (207 
men [81.5 ],  47 women [18.5 ]),  with a mean age 
of 65.7±10.5 years,  are shown in Table 1.  Thirty-
two (12.6 ) of the patients had an ASA physical sta-
tus of 3 or 4.  The mean SMI values were 47.6±7.3  
cm2/m2 for men and 37.4±5.3 cm2/m2 for women,  and 
118 patients (46.5 ) were categorized as being sarco-
penic.
　 The sarcopenic group (n＝118) was signiﬁcantly 
older (p＜0.001) and had signiﬁcantly lower BMI val-
ues (p＜0.001) than the non-sarcopenic group (n＝136).  
The ASA physical status,  etiology of liver disease,  
comorbidities,  and operative factors were not signiﬁ-
cantly diﬀerent between the 2 groups.  With regard to 
the pathological factors and tumor stage,  sarcopenia 
was correlated with the presence of microvascular 
invasions (p＝0.003) and the tumor stage (p＝0.015).
　 Overall survival after hepatectomy for HCC.
Fig.  2 shows the overall survival curves after hepa-
tectomy for HCC for the 2 groups in the Kaplan-
Meier analysis.  After the median follow-up of 41.8 
months (range 1-109 months),  64 patients (25.2 ) 
died from the following causes: cancer progression,  
43; liver failure,  5; postoperative mortality,  5; infec-
tion,  3; and other reasons,  8.  The overall 5-year 
survival rate was signiﬁcantly lower in the sarcopenic 
group compared to the non-sarcopenic group (58.2  
vs. 82.4 ,  log rank p＝0.0002).
　 Prognostic factors for overall survival after 
hepatectomy for HCC. Table 2 shows the results 
of the univariate and multivariate analyses to identify 
the prognostic factors closely related to long-term 
survival after hepatectomy.  In the univariate analysis,  
9 variables were independently poor prognostic fac-
tors.  In the multivariate analysis,  4 variables were 
signiﬁcantly poor prognostic factors: sarcopenia (p＝
0.002),  ASA physical status of 3 or 4 (p＝0.001),  the 
presence of multiple tumors (p＝0.014),  and microvas-
cular invasion (p＜0.001).
　 Simple scoring system using preoperative risk 
factors. A simple scoring system was applied for 
all patients,  with 1 point assigned to each signiﬁcant 
preoperative risk factor―sarcopenia and ASA phys-
ical status of 3 or 4―using a similar HR as in the 
multivariate analysis except for pathological factors.  
We divided the patients into three groups according to 
these potential risk factors: the Risk 0 group (nega-
tive for both sarcopenia and poor ASA status,  n＝120),  
the Risk 1 group (positive for either sarcopenia or 
poor ASA status,  n＝118),  and the Risk 2 group 
(positive for both sarcopenia and poor ASA status,  
n＝16).
　 Fig.  3 shows the overall survival curves after 
hepatectomy for HCC for these 3 groups,  based on the 
Kaplan-Meier analysis.  The overall 5-year survival 
rates after hepatectomy were 85.6  for the Risk 0 
group,  62.4  for the Risk 1 group,  and 22.8  for the 
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Fig. 1　 CT scan of the L3 region showing the total skeletal mus-
cle mass (green).
Risk 2 group (log rank p＜0.0001) (Table 3).  In the 
Cox proportional hazard model,  all diﬀerences 
between the Risk 0 group and other groups were sig-
niﬁcant.  The postoperative mortality rate was signiﬁ-
cantly highest in the Risk 2 group (p＝0.007).
Discussion
　 This retrospective study demonstrated that sarco-
penia and poor ASA status are independent predictors 
of poor overall survival in patients undergoing hepa-
tectomy for HCC,  and we identiﬁed the eﬃciency of a 
simple scoring system using preoperative risk factors 
that can detect a high postoperative mortality rate and 
a low survival rate.  The primary ﬁnding is similar to 
that of previous reports,  in which sarcopenia was 
associated with overall survival after hepatectomy for 
HCC [7,9].
　 Studies aimed at identifying the prognosis after 
surgery have conventionally focused on tumor-speciﬁc 
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Table 1　 Demographic and clinicopathological factors of the HCC patients with or without sarcopenia who underwent hepatectomy
All patients
(n＝254)
Non-sarcopenic
(n＝136)
Sarcopenic
(n＝118) p-value
Demographic variables:
Men/women 207/47 114/22 93/25 0.31†
Mean age (yrs) 65.7±10.5 63.1±10.3 68.6±10.0 ＜0.001＊
BMI (kg/m2) 23.7±3.5 25.2±3.3 22.0±3.0 ＜0.001＊
Body composition:
　L3 SMI in men (n＝207,  cm2/m2) 47.6±7.3 52.8±4.7 41.1±3.9 ＜0.001＊
　L3 SMI in women (n＝47,  cm2/m2) 37.4±5.3 41.8±3.8 33.5±2.9 ＜0.001＊
ASA physical status:
　Grades 1-2/3-4 222/32 120/16 102/16 0.67†
Etiology of liver disease:
　HBV and/or HCV 171 89 82 0.49†
　Others 83 47 36
Laboratory values:
　Alb (g/dl) 4.0±0.47 4.1±0.48 4.0±0.45 0.11＊
　Plt (×104/µl) 18.3±8.2 17.4±7.4 19.5±9.0 0.09＊
Tumor markers:
　AFP (ng/ml) 3,689±21,461 1,438±5,650 6,283±30,766 0.77＊
Comorbidity:
　Diabetes 75 35 40 0.15†
　Hypertension 104 58 46 0.55†
Operative factors
　Type of hepatectomy:
　 lobectomy 97 48 49 0.31†
　 segmentectomy 157 88 69
Operative time (min) 285±111 284±97 287±125 0.35＊
Blood loss (ml) 949±965 910±894 994±1,042 0.61＊
Tumor characteristics
　Tumor size (cm) 4.7±3.5 4.2±2.9 5.3±4.1 0.32＊
　Tumor number:
　Solitary/Multiple 175/79 95/41 80/38 0.72†
Poor diﬀerentiation 35 16 19 0.32†
Microvascular invasion 76 30 46 0.003†
Tumor stage:
　I/II/III/IV 28/110/83/33 16/63/48/9 12/47/35/24 0.015†
Major postoperative complications 35 16 19 0.32†
Postoperative mortality 5 1 4 0.13†
＊Mann-Whitney U test,  †Fisherʼs exact test or χ2-test.  Values are mean ± SD unless otherwise indicated.
BMI,  body mass index; SMI,  skeletal muscle index; ASA,  American Society of Anesthesiologists; HBV,  hepatitis B virus; HCV,  hepati-
tis C virus; Alb,  albumin; Plt,  platelet; AFP,  alpha-fetoprotein.
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Table 2　 Univariate and multivariate analyses of prognostic factors associated with overall survival in patients who underwent hepatectomy
Univariate analysis Multivariate analysis
Variable No. of patients(n＝254) HR 95% CI p-value
＊ HR 95% CI p-value＊
Sarcopenia 118 2.87 1.72-4.98 ＜0.001 2.28 1.34-4.01 0.002
Male 207 1.51 0.79-3.28 0.23
Age ( 70 yrs) 103 1.16 0.70-1.91 0.52
BMI ( 25 kg/m2) 83 0.85 0.48-1.44 0.56
ASA ( grade 3) 32 3.28 1.80-5.67 ＜0.001 3.17 1.61-5.94 0.001
HBV and/or HCV 171 0.85 0.52-1.45 0.55
Alb (＜3.6 g/dl) 40 1.43 0.74-2.54 0.27
Plt (＜10×104/µl) 33 0.89 0.39-1.76 0.76
AFP ( 400 ng/ml) 43 1.95 1.07-3.36 0.029 1.00 0.51-1.86 0.99
Diabetes 75 1.96 1.18-3.20 0.01 1.06 0.61-1.82 0.83
Hypertension 104 1.08 0.65-1.77 0.77
Tumor size ( 50 mm) 77 3.49 2.13-5.73 ＜0.001 1.23 0.66-2.29 0.52
Tumor number 2 tumors) 79 1.91 1.16-3.12 0.012 1.95 1.15-3.31 0.014
Poor diﬀerentiation 35 2.58 1.37-4.56 0.005 1.24 0.60-2.40 0.55
Microvascular invasion 76 5.71 3.46-9.62 ＜0.001 4.04 2.17-7.53 ＜0.001
Major postoperative complications 35 2.34 1.22-4.17 0.001 1.25 0.60-2.42 0.53
＊Cox proportional hazard model.
BMI,  body mass index; ASA,  American Society of Anesthesiologists; HBV,  hepatitis B virus; HCV,  hepatitis C virus; Alb,  albumin; Plt,  
platelet; AFP,  alpha-fetoprotein.
Table 3　 Short-term and long-term outcomes after hepatectomy, based on the results of the risk scoring system
No. of risk factors Postoperativemortality p-value
＊ 3-year survival rate
(%)
5-year survival rate
(%) HR 95% CI p-value
†
0 (Risk 0 group,  n＝120) 1 (0.83%) 0.007 89.5% 85.6% - - -
1 (Risk 1 group,  n＝118) 2 (1.69%) 69.8% 62.4% 3.30 1.84-6.29 ＜0.0001
2 (Risk 2 group,  n＝16) 2 (12.5%) 34.3% 22.8% 9.38 4.00-21.2 ＜0.0001
＊Fisherʼs exact test or χ2-test, †Cox proportional hazard model.
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Fig. 3　 Overall survival curves after hepatectomy for patients in 
the Risk 0,  Risk 1,  and Risk 2 groups. p＜0.0001 (log rank test).
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Fig. 2　 Overall survival curve after hepatectomy in patients with 
and without sarcopenia p＝0.0002 (log rank test).
factors [5]; however,  the prognosis after surgery is 
multifactorial and depends on not only tumor-speciﬁc 
factors but also preoperative factors of the hosts.  
Among the preoperative factors,  our present ﬁndings 
demonstrated that an ASA physical status 3 was a 
signiﬁcant factor for overall survival,  as was sarcope-
nia.  Although the ASA physical status was evaluated 
by anesthesiologists to assess the surgical risk,  it is 
also useful to assess the general condition of patients.
　 Gerontologists have focused on frailty to establish 
a more precise deﬁnition of anility [21-23].  Frailty 
is assessed by a subjective evaluation of unintentional 
weight loss,  exhaustion,  weakness,  slow walking speed,  
and low levels of physical activity.  Thus,  sarcopenia 
has been investigated as an objective measurement of 
frailty and a good predictor of poor outcome in various 
types of cancers [8].
　 Sarcopenia is deﬁned as a syndrome characterized 
by the loss of skeletal mass and strength that occurs 
with aging [24].  The European Working Group on 
Sarcopenia in Older People recommended that both 
muscle mass and muscle function be evaluated for the 
diagnosis of sarcopenia [25].  However,  it is diﬃcult 
to evaluate muscle function in a retrospective study.  
Here we evaluated only muscle mass using preopera-
tive CT images,  which is assumed to be an objective 
and precise assessment of sarcopenia [21-23].
　 Regarding CT-based cut-oﬀ values,  we were uncer-
tain of the appropriate deﬁnition for the assessment of 
sarcopenia,  and sex-speciﬁc cut-oﬀ values for sarcope-
nia for the Japanese population are lacking.  Prado et 
al.  reported the cut-oﬀ values for sarcopenia as L3 
SMI 52.4 cm2/m2 for men and 38.5 cm2/m2 for 
women [19].  However,  van Vledder et al.  reported 
cut-oﬀ values of L3 SMI 43.75 cm2/m2 for men and 
41.10 cm2/m2 for women [20].  Because the physique 
diﬀers between Western and Japanese people,  it is 
possible that we did not accurately evaluate sarcopenia 
using the cut-oﬀ values for Western populations.  In 
the present study,  we calculated the sex-speciﬁc cut-
oﬀ values as L3 SMI 46.4 cm2/m2 for men and 
37.6 cm2/m2 for women.  Using these cut-oﬀ values,  
we found that the prevalence of sarcopenia in our HCC 
patient population was 46.5 .
　 With regard to the overall survival curves,  we 
found a strong correlation between sarcopenia and 
overall survival (Fig.  2).  The 5-year survival rate 
following hepatectomy was 58.2  among the patients 
with sarcopenia and 82.4  among those without sarco-
penia,  and the sarcopenic group had extremely poor 
survival.  The molecular mechanism of sarcopenia is 
not fully understood.  Skeletal muscle was recently 
identiﬁed as a secretory organ in which cytokines and 
other peptides are produced and released by muscle 
ﬁbers [26].  Interleukin (IL)-6,  an inﬂammatory cyto-
kine released from skeletal muscle,  aﬀects liver 
metabolism,  and high IL-6 levels are associated with 
an increased risk of HCC [27].  The activation of IL-6 
might thus be related to sarcopenia and HCC progres-
sion.
　 Moreover,  the levels of insulin-like growth factor 
1 (IGF-1),  an endocrine hormone produced primarily 
by the liver,  are lower in older and sarcopenic patients 
[26,28].  Low IGF-1 levels are correlated with 
advanced clinicopathological parameters and poor sur-
vival in patients with HCC [29].  In the present study,  
sarcopenia was correlated with aging,  advanced clini-
copathological parameters,  and poor survival.  Further 
studies to elucidate the molecular mechanism between 
sarcopenia and HCC are needed.
　 Our multivariate analysis revealed that sarcopenia 
and ASA physical status of 3 or 4 were the only prog-
nostic preoperative host factors related to overall 
survival after hepatectomy for HCC (Table 2).  
Similar to previous reports,  tumor-speciﬁc factors 
such as multiple tumors and microvascular invasion,  
which is the T factor as per the guidelines of the 
Liver Cancer Study Group of Japan,  were strong 
independent factors associated with survival [30,31],  
but tumor size and diﬀerentiation were not signiﬁ-
cantly associated with survival.
　 The results of a simple scoring system using preop-
erative risk factors are presented in Table 3.  In this 
scoring system,  we selected preoperative host predic-
tors to establish a simple comprehensive system and 
excluded pathological factors that were determined 
only after surgery and diﬃcult to accurately assess 
before surgery.  Only 16 patients had both sarcopenia 
and a poor ASA status (the Risk 2 group).  This group 
had the highest postoperative mortality rate and the 
lowest 3-year and 5-year survival rates (Fig.  3).  At 
the same time,  some patients (n＝118) had one risk 
factor (the Risk 1 group)―sarcopenia or poor ASA 
status―and the other patients (n＝120) had no pre-
operative factor (the Risk 0 group).
　 The ASA physical status is a subjective classiﬁca-
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tion system and similar to the “eyeball test” [32],  
which detects frailty,  but is an independent predictor 
of overall survival.  However,  sarcopenia is an objec-
tive assessment of frailty and is an important risk 
factor.  Therefore,  we were able to identify the poten-
tial risk for poor prognosis using a simple scoring 
system that represents both subjective and objective 
evaluations of host frailty.
　 Strategies for the assessment and management of 
sarcopenia including early preoperative detection and 
active interventions (such as nutritional treatment and 
exercise) may improve the postoperative outcomes for 
surgically high-risk patients with HCC.  In several 
studies,  combined nutrition and exercise interventions 
were the most eﬀective strategies for sarcopenia man-
agement [33-36].  In the perioperative management of 
hepatectomy,  in particular,  perioperative nutritional 
support reduced postoperative complications [35],  
and early enteral nutrition had obvious advantages 
compared to parenteral nutrition [36].  However,  no 
therapeutic algorithm for improving postoperative 
outcomes in patients with sarcopenia has been estab-
lished.  Future studies should be conducted to develop 
a method for identifying sarcopenia and establishing 
preoperative interventional treatments for sarcopenic 
patients.
　 Despite our important ﬁndings,  this study has a few 
limitations.  First,  this was a retrospective,  sin-
gle-center study,  and there may thus have been a 
potential selection bias for the patients for hepatec-
tomy.  Second,  due to the retrospective design of the 
study we were unable to assess aspects of functional 
muscle status such as grip strength,  walking speed,  or 
levels of exhaustion.  Third,  the ASA physical status 
is subjective and sometimes evaluated diﬀerently by 
diﬀerent anesthesiologists.  Finally,  we considered 
our cut-oﬀ values for SMI to be accurate for the eval-
uation of sarcopenia.  Because there is no appropriate 
deﬁnition of CT-based assessment for sarcopenia in the 
Japanese,  we used receiver operating characteristic 
curves to determine the cut-oﬀ values for SMI.
　 In conclusion,  the result of our study indicates that 
in addition to a poor ASA physical status,  sarcopenia 
is a unique,  independent preoperative predictor of 
poor outcomes after hepatectomy.  The assessment of 
sarcopenia and ASA status is an easy and feasible 
method.  Furthermore,  our new scoring system,  which 
represents subjective and objective frailty,  might help 
researchers develop comprehensive approaches for 
decision-making regarding surgical indications.
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